RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
2.550
-0.110 (-4.14%)
At close: Apr 1, 2025, 4:00 PM
2.597
+0.047 (1.83%)
After-hours: Apr 1, 2025, 4:33 PM EDT
RedHill Biopharma Revenue
RedHill Biopharma had revenue of $1.29M in the quarter ending June 30, 2024, a decrease of -28.40%. This brings the company's revenue in the last twelve months to $3.71M, down -89.63% year-over-year. In the year 2023, RedHill Biopharma had annual revenue of $6.53M, down -89.43%.
Revenue (ttm)
$3.71M
Revenue Growth
-89.63%
P/S Ratio
0.56
Revenue / Employee
$69,943
Employees
53
Market Cap
3.27M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.53M | -55.27M | -89.43% |
Dec 31, 2022 | 61.80M | -23.96M | -27.94% |
Dec 31, 2021 | 85.76M | 21.40M | 33.25% |
Dec 31, 2020 | 64.36M | 58.07M | 923.03% |
Dec 31, 2019 | 6.29M | -2.07M | -24.75% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RDHL News
- 14 days ago - RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation - PRNewsWire
- 20 days ago - RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results - PRNewsWire
- 4 weeks ago - RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum - PRNewsWire
- 5 weeks ago - RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties - PRNewsWire
- 2 months ago - RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer - PRNewsWire
- 2 months ago - RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published - PRNewsWire
- 4 months ago - Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development - PRNewsWire
- 4 months ago - RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court - PRNewsWire